Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -14.87
- Piotroski Score 0.00
- Grade Buy
- Symbol (ANVS)
- Company Annovis Bio, Inc.
- Price $6.94
- Changes Percentage (-6.34%)
- Change -$0.47
- Day Low $6.85
- Day High $7.52
- Year High $22.49
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/27/2025
- Fiscal Year End N/A
- Average Stock Price Target $26.00
- High Stock Price Target $30.00
- Low Stock Price Target $21.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$5.14
- Trailing P/E Ratio -1.2
- Forward P/E Ratio -1.2
- P/E Growth -1.2
- Net Income $-56,204,313
Income Statement
Quarterly
Annual
Latest News of ANVS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Will Annovis Bio (NYSE:ANVS) Spend Its Cash Wisely?
Investing in unprofitable businesses can be profitable, but risky due to potential cash burn issues. Annovis Bio (NYSE: ANVS) had a short cash runway of 7 months in September 2024, with a cash burn of...
By Yahoo! Finance | 3 days ago -
Annovis Bio, Inc. (NYSE:ANVS) surges 24%; retail investors who own 56% shares profited along with insiders
Retail investors own a majority stake of 56% in Annovis Bio, giving them significant influence over management decisions. Institutional investors also hold a portion, indicating confidence in the comp...
By Yahoo! Finance | 2 months ago -
Annovis Bio, Inc. (ANVS) Stock Price, News, Quote & History
Annovis Bio is a drug platform company working on treatments for neurodegenerative diseases like Alzheimer's and Parkinson's. They have lead candidates in various stages of clinical trials, aiming to ...
By Yahoo! Finance | 4 months ago
